°Ç¸ç³Ô¹Ï

Skip to main content

Our governance

The main decision-making, executive and managerial bodies at the Medicines and Healthcare products Regulatory Agency (MHRA).

Corporate governance

We’re governed by a unitary agency board with an equal number of executive and non-executive directors, and non-executive chair, supported by three board assurance committees.

The board

The unitary board is responsible for advising on the strategic direction of the agency, ensuring that targets set out in the business plan and agreed with ministers, are met.

The board supports the Chief Executive in the effective delivery of services and overall performance by providing leadership, developing strategy, advising on the delivery of policies, maintaining high standards of corporate governance, scrutinising performance and ensuring that controls are in place to manage risk.

The board does not have involvement in any regulatory decisions affecting medicines or medical devices. These are the responsibility of the Chief Executive and Executive Committee.

Members

The structure of the Board remains unitary, comprising 13 members: six executive members, six non-executive directors, and a non-executive Chair. The Director of Communications and Engagement and the Chief People Officer have a standing invitation to attend Board in a non-voting capacity. Other executives will be invited to attend on an ad-hoc basis to present relevant items.

Members are:

The Board is supported by three assurance committees:

  • Audit and Risk Assurance committee, chaired by Michael Whitehouse OBE
  • Regulation and Safety committee, chaired by Dr Paul Goldsmith
  • People and Public Engagement committee, chaired by Mercy Jeyasingham MBE

Board members’ declarations of interest

(PDF, 197 KB, 4 pages)

(PDF, 215 KB, 8 pages)

MHRA Board terms of reference

(PDF, 249 KB, 13 pages)

MHRA Board Meetings in 2026

The MHRA Board Meetings in 2026 will be held in public on the below dates:

  • Tuesday, 7 July 2026

Our next MHRA Board Meeting held in public will be conducted virtually by webinar on Tuesday, 7 July 2026 from 10:00AM until 12.30PM (GMT).

MHRA Board minutes

Previous minutes and recordings are available on .

Previous Board meetings and public sessions

MHRA Board Meeting held in public on 20 January 2026

(PDF, 22.2 MB, 87 pages)

MHRA Board meeting held on 8 July 2025

(PDF, 1.5 MB, 68 pages)

MHRA Board meeting held on 18 March 2025

(PDF, 2.01 MB, 64 pages)

MHRA Board meeting held on 17 September 2024

(PDF, 2.64 MB, 117 pages)

MHRA Board meeting held on 9 July 2024

(PDF, 10.4 MB, 98 pages)

MHRA Board meeting held in public on 21 May 2024

(PDF, 2.79 MB, 98 pages)

MHRA Board meeting held in public on 19 March 2024

(PDF, 2.7 MB, 81 pages)

MHRA Board meeting held in public on 16 January 2024

(PDF, 1.73 MB, 66 pages)

MHRA Board meeting held in public on 21 November 2023

(PDF, 3.89 MB, 114 pages)

MHRA Board meeting held in public on 19 September 2023

(PDF, 3.19 MB, 99 pages)

MHRA Board meeting held in public on 11 July 2023

(PDF, 1.21 MB, 72 pages)

MHRA Board meeting held in public on 16 May 2023

(PDF, 2.7 MB, 80 pages)

MHRA Board meeting held in public on 21 March 2023

(PDF, 2.04 MB, 107 pages)

MHRA Board meeting held in public on 17 January 2023

(PDF, 1.74 MB, 62 pages)

MHRA Board meeting held in public on 15 November 2022

(PDF, 2.72 MB, 81 pages)

Executive Committee

The Executive Committee is the highest executive decision-making body of the agency and is chaired by the Chief Executive Lawrence Tallon. The Executive Committee ensures that the decisions which are critical to the agency are taken in a timely way, at the right level in the organisation, by the right people with the right evidence. This ensures clear accountability for delivery, strong management of risk, transparent priorities and that business is conducted in a smooth and predictable fashion. It is comprised of:

Contents